Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study

References

• Almehmadi Y, Yassin DJ, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male 2015;18:186–94.
   PubMed Web of Science ®Google Scholar
• Morelli A, Corona G, Filippi S, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Investig 2007;30:880–8.
   PubMed Web of Science ®Google Scholar
• Rabijewski M, Papierska L, Kuczerowski R, Piatkiewicz P. Hormonal determinants of erectile dysfunction and lower urinary tract symptoms in middle-aged and elderly men with prediabetes. Aging Male 2015;18:256–64.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Ther Adv Urol 2009;1:179–97.
   PubMedGoogle Scholar
• Aversa A, Francomano D, Lenzi A. Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients? Expert Opin Pharmacother 2015;16:625–8.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment – a systematic review. Eur Urol 2014;65:99–112.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Bhasin S, Travison TG, et al. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013;1:913–18.
   PubMed Web of Science ®Google Scholar
• Carosa E, Martini P, Brandetti F, et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol 2004;61:382–6.
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli R, Vicari E, et al. Physical activity and erectile dysfunction in middle-aged men. J Androl 2012;33:154–61.
   PubMed Web of Science ®Google Scholar
• Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med 2013;10:120–9.
   PubMed Web of Science ®Google Scholar
• Aversa A, Sarteschi LM. The role of penile color-duplex ultrasound for the evaluation of erectile dysfunction. J Sex Med 2007;4:1437–47.
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli RA, Vicari E, et al. New immunophenotype of blood endothelial progenitor cells and endothelial microparticles in patients with arterial erectile dysfunction and late-onset hypogonadism. J Androl 2011;32:509–17.
   PubMedGoogle Scholar
• Speel TG, van Langen H, Wijkstra H, Meuleman EJ. Penile duplex pharmaco-ultrasonography revisited: revalidation of the parameters of the cavernous arterial response. J Urol 2003;169:216–20.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Lotti F, et al. Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J Sex Med 2014;11:173–86.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18:5–15.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impotence Res 1999;11:319–26.
   PubMed Web of Science ®Google Scholar
• Karvonen J, Vuorimaa T. Heart rate and exercise intensity during sports activities. Practical application. Sports Med 1988;5:303–11.
   PubMed Web of Science ®Google Scholar
• Trichopoulou A. Traditional Mediterranean diet and longevity in the elderly: a review. Public Health Nutr 2004;7:943–7.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124–37.
   PubMed Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567–76.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang JR, Yang LY, Liu ZT. Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med Hypoth 2008;70:1021–3.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006;38:61–8.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Morelli A, Luconi M, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409–16. discussion 16
   PubMed Web of Science ®Google Scholar
• Paduch DA, Brannigan RE, Fuchs EF, et al. The laboratory diagnosis of testosterone deficiency. Urology 2014;83:980–8.
   PubMed Web of Science ®Google Scholar
• Goldfischer ER, Kim ED, Seftel AD, et al. Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. Urology 2014;83:1326–33.
   PubMed Web of Science ®Google Scholar
• Zhang W, Li P, Cai ZK, et al. Safety and efficacy of L-carnitine and tadalafil for late-onset hypogonadism with ED: a randomized controlled multicenter clinical trial. Zhonghua Nan Ke Xue = National J Androl 2014;20:133–7.
   PubMedGoogle Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 2016;19:64–9.
   PubMed Web of Science ®Google Scholar
• Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Hormone Res 2009;37:52–61.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014;65:968–78.
   PubMed Web of Science ®Google Scholar
• Aslan Y, Guzel O, Balci M, et al. The impact of metabolic syndrome on serum total testosterone level in patients with erectile dysfunction. Aging Male 2014;17:76–80.
   PubMed Web of Science ®Google Scholar
• Ho CH, Wu CC, Chen KC, et al. Erectile dysfunction, loss of libido and low sexual frequency increase the risk of cardiovascular disease in men with low testosterone. Aging Male 2016. [Epub ahead of print]. doi: 10.3109/13685538.2015.1129400.
   PubMed Web of Science ®Google Scholar
• Russo GI, Castelli T, Privitera S, et al. Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. BJU Int 2015;116:791–6.
   PubMed Web of Science ®Google Scholar
• Leoni LA, Fukushima AR, Rocha LY, et al. Physical activity on endothelial and erectile dysfunction: a literature review. Aging Male 2014;17:125–30.
   PubMed Web of Science ®Google Scholar
• Pofi R, Gianfrilli D, Badagliacca R, et al. Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): how do they work? J Endocrinol Investig 2016;39:131–42.
   PubMed Web of Science ®Google Scholar
• Chen L, Staubli SE, Schneider MP, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol 2015;68:674–80.
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902–12.
   PubMed Web of Science ®Google Scholar
• Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med 2010;7:2201–8.
   PubMed Web of Science ®Google Scholar
• Mulhall J, Teloken P, Barnas J. Vasculogenic erectile dysfunction is a predictor of abnormal stress echocardiography. J Sex Med 2009;6:820–5.
   PubMed Web of Science ®Google Scholar
• Demir O, Demir T, Kefi A, et al. Penile vascular impairment in erectile dysfunction patients with metabolic syndrome: penile Doppler ultrasound findings. Urol Int 2009;82:175–8.
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli R, Vicari E, et al. Aerobic physical activity improves endothelial function in the middle-aged patients with erectile dysfunction. Aging Male 2011;14:265–72.
   PubMed Web of Science ®Google Scholar
• Hisasue S. Contemporary perspective and management of testosterone deficiency: modifiable factors and variable management. Int J Urol 2015;22:1084–95.
   PubMed Web of Science ®Google Scholar
• Di Luigi L, Sgro P, Fierro V, et al. Prevalence of undiagnosed testosterone deficiency in aging athletes: does exercise training influence the symptoms of male hypogonadism? J Sex Med 2010;7:2591–601.
   PubMed Web of Science ®Google Scholar